OraSure Technologies (OSUR) Projected to Post Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect OraSure Technologies to post earnings of ($0.16) per share and revenue of $27.7160 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 5:00 PM ET.

OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.02). OraSure Technologies had a negative net margin of 59.76% and a negative return on equity of 16.45%. The company had revenue of $26.76 million during the quarter, compared to the consensus estimate of $26.44 million.

OraSure Technologies Stock Performance

Shares of OSUR stock opened at $2.95 on Monday. OraSure Technologies has a 52-week low of $2.08 and a 52-week high of $3.82. The firm has a market capitalization of $212.31 million, a P/E ratio of -3.17 and a beta of 0.89. The stock has a 50 day moving average price of $3.04 and a 200 day moving average price of $2.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, OraSure Technologies currently has an average rating of “Reduce” and an average target price of $3.00.

Insider Buying and Selling

In other OraSure Technologies news, CEO Manner Carrie Eglinton purchased 32,300 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was purchased at an average cost of $2.93 per share, with a total value of $94,639.00. Following the purchase, the chief executive officer owned 2,190,874 shares of the company’s stock, valued at approximately $6,419,260.82. The trade was a 1.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kenneth J. Mcgrath purchased 32,300 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average cost of $2.93 per share, with a total value of $94,639.00. Following the completion of the purchase, the chief financial officer directly owned 589,562 shares in the company, valued at $1,727,416.66. The trade was a 5.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 108,643 shares of company stock valued at $321,407 over the last three months. 3.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OSUR. Kotler Kevin purchased a new position in OraSure Technologies during the 4th quarter worth $4,359,000. Millennium Management LLC increased its holdings in OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after purchasing an additional 878,151 shares during the period. Archon Capital Management LLC purchased a new position in OraSure Technologies during the 4th quarter worth $1,388,000. Cannell Capital LLC increased its holdings in OraSure Technologies by 33.7% during the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after purchasing an additional 470,536 shares during the period. Finally, UBS Group AG increased its holdings in OraSure Technologies by 98.2% during the 3rd quarter. UBS Group AG now owns 722,520 shares of the medical instruments supplier’s stock worth $2,319,000 after purchasing an additional 358,016 shares during the period. 93.50% of the stock is currently owned by hedge funds and other institutional investors.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.